Sunovion Must Regroup After Setback With Dasotraline In ADHD
Executive Summary
Sunovion must find a new path forward for its dasotraline in attention deficit/hyperactivity disorder (ADHD), following a complete response letter from the US FDA.
You may also be interested in...
Supernus’ ADHD Drug Hits Phase III Endpoint As Filing Beckons
The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.
Sunovion's Dasotraline To Be Filed In US For ADHD Despite Uncertainties
Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.
Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.